CNBX - Cannabics Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.04
+0.05 (+5.58%)
As of 10:47AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.99
Open0.95
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.93 - 1.05
52 Week Range0.60 - 2.99
Volume121,524
Avg. Volume132,307
Market Cap125.357M
Beta-5.73
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    Join Cannabics Pharmaceuticals at the National Cannabis Industry Association's Cannabis Business Summit and Expo Held at San Jose Convention Center, California USA, July 25-27, 2018

    TEL AVIV, Israel and BETHESDA, Maryland, July 11, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that senior members of its team will be attending the National Cannabis Industry Association Business Conference and Expo, to be held in San Jose convention center, California, USA, on July 25th-27th 2018, and will be available for one on one meetings. The National Cannabis Industry Association, or NCIA, is the industry's premier organization in the United States, and the Business conference and expo held in San Jose is their 5th and largest event to date. In attendance will be Mr. Eyal Barad, Co-Founder and CEO, alongside Mr. Noam Permont, VP of Business Development.

  • PR Newswire13 days ago

    Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)

    TEL AVIV, Israel and BETHESDA, Maryland, July 3, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), leader in personalized cannabis medicine focused on cancer and its side effects, announced today that it has concluded its clinical trial held at Rambam Medical Center.  The Oncology Center at Rambam Medical Center is recognized by the European Society for Medical Oncology (ESMO) as a designated Center of Integrated Oncology and Palliative Care.

  • Cannabics Pharmaceuticals Enters a Memorandum of Understanding With Clinical-Stage Biopharmaceutical Company Focused on the Treatment of Ophthalmic Disorders
    PR Newswire17 days ago

    Cannabics Pharmaceuticals Enters a Memorandum of Understanding With Clinical-Stage Biopharmaceutical Company Focused on the Treatment of Ophthalmic Disorders

    TEL AVIV, Israel and BETHESDA, Maryland, June 29, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabis medicine focused on cancer and its side effects, announced today that it has entered a memorandum of understanding with a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. The new entity will focus on exploring the potential of alleviating the effects of eye disorders and infections using cannabinoids, while reducing use of steroid based products which are currently widely used.

  • PR Newswire20 days ago

    Cannabics Pharmaceuticals to Participate in the International Cannabis Research Society Annual Forum in Leiden, the Netherlands

    TEL AVIV, Israel and BETHESDA, Maryland, June 26, 2018 /PRNewswire/ --  Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabis medicine focused on cancer and its side effects, announced today that senior members of its scientific team will be attending the International Cannabinoid Research Society conference, to be held in Leiden, the Netherlands July 1st – 4th 2018, and will be available for one on one meetings. The International Cannabinoid Research Society, ICRS, a non-political organization, is dedicated to scientific research in all fields of cannabinoids, ranging from biochemical, chemical and physiological studies of the endogenous cannabinoid system.

  • FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board
    CNW Group20 days ago

    FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board

    FSD Pharma Appoints Dr. Zohar Koren as Head of Scientific Advisory Board

  • PR Newswire2 months ago

    Join Cannabics Pharmaceuticals at LCBC Cannabis Professional Conference Held at MTCC, Toronto, Canada, May 25-27, 2018

    TEL AVIV, Israel and BETHESDA, Maryland , May 24, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals (OTCQB: CNBX), a US bio-pharma company developing novel cannabis-based, personalized medicine solutions ...

  • Cannabics Pharmaceuticals Hires Two New Scientists to Further Develop Cannabinoid Diagnostic Tests and Treatments for Cancer
    PR Newswire2 months ago

    Cannabics Pharmaceuticals Hires Two New Scientists to Further Develop Cannabinoid Diagnostic Tests and Treatments for Cancer

    TEL AVIV, Israel and BETHESDA, Maryland, May 22, 2018 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), leader in cannabinoid diagnostic tests for personalized cancer treatment, announced today the appointment of Haleli Sharir, Ph.D. as principal scientist and Nir Kfir, Ph.D. as senior scientist. The two new team members will support Cannabics' data-discovery process with the goal of identifying new cannabinoid diagnostic tests and treatments for cancer.

  • PR Newswire2 months ago

    Cannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities

    Dr. Zohar will support strategic business planning as Cannabics enters $10 million Standby Equity Distribution Agreement with YAII PN, Ltd. Cannabics Pharmaceuticals Inc. (CNBX), leader in cannabinoid diagnostic tests for personalized cancer treatment, today announced that CEO of Life Source Partners Ltd., Muriel Zohar, Ph.D, MBA, will be working with Cannabics to advance personalized and palliative cannabinoid cancer care.

  • PR Newswire4 months ago

    Cannabics Pharmaceuticals Receives Positive Results From Preclinical Study on Antitumor Effects of Cannabinoids

    Cannabics Pharmaceuticals Inc. (CNBX), a leader in cannabinoid diagnostic tests for personalized cancer therapy, today announced encouraging results from a preclinical study on the antitumor effects of cannabinoids on cancerous tumor cells. The study indicates that cancer cells derived from patient blood samples are differentially sensitive to the main active compounds in cannabis, tetrahydrocannabinol (THC) and tetrahydrocannabinolic acid (THCA).

  • PR Newswire5 months ago

    Cannabics' Dr. Moran Grinberg to Speak at the Annual CannaTech Conference

    Cannabics Pharmaceuticals, Inc. (CNBX) announced today that Dr. Moran Grinberg, VP of R&D, will speak at the Annual CannaTech Conference to be held in Tel-Aviv, Israel, March 19th-20th. CannaTech is a yearly conference of acknowledged leaders in science, research, medicine and government policy relating to medical cannabis. Dr. Grinberg is appearing as a Key Note speaker for the Session "Bringing Personalized Cannabinoid-based Medicine to the World".

  • PR Newswire5 months ago

    Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application

    Cannabics Pharmaceuticals Inc. (CNBX), a US public biotechnology company dedicated to the development of personalized anti-cancer diagnostics and palliative treatments based on the therapeutic properties of cannabis, announced the appointment of Yasha Borstein as the company's Chief Data Officer. With extensive experience spanning big data analytics, machine learning, AI and software development alongside an extended track record in enterprise risk management, Yasha Borstein will oversee the design and implementation of a data governance policy for the company.

  • Cannabics Pharmaceuticals Inc :CNBX-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018
    Capital Cube6 months ago

    Cannabics Pharmaceuticals Inc :CNBX-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018

    Categories: Yahoo FinanceGet free summary analysis Cannabics Pharmaceuticals Inc reports financial results for the quarter ended November 29, 2017. Highlights Summary numbers: Revenues of USD 0.00 million, Net Earnings of USD -0.54 million. Gross margins widened from 0% to 89.20% compared to the same period last year, operating (EBITDA) margins now -30,508.52% from -205.76%. Change in operating ... Read more (Read more...)

  • ACCESSWIRE6 months ago

    Cannabics Pharmaceuticals, Breakthrough Cannabis Medications, Analysts Review and Outlook

    NEW YORK, NY / ACCESSWIRE / January 10, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...

  • PR Newswire6 months ago

    Cannabics Pharmaceuticals Files an International Patent Application on Methods for Testing and Predicting Therapeutic Effectiveness of Cannabinoids for Cancer Patients

    Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an international patent application with the PCT authorities on methods for testing which cannabinoids or combinations of cannabinoids are likely be effective in individual patients. The determination is made by testing the effects of cannabinoids on CTCs (Circulating Tumor Cells) and biopsies of cancer patients. The integrated approach brings together cannabinoids research, Genetic markers, CTC counting and detection methods, and a drug sensitivity test for cannabinoids developed by Cannabics Pharmaceuticals.

  • PR Newswire8 months ago

    Cannabics Pharmaceuticals Received a New Research License for Characterization of Anti-Tumor Activity of Cannabinoids

    TEL-AVIV, Israel, Nov. 28, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has received a new research license from the Israeli Ministry of Health for the Characterization of anti-tumor activity of cannabinoids. The new license will enable the company to continue our vision of developing an ecosystem for creation of diagnostic tools and bringing to the market diagnostic services for cancer patients who are medicated with cannabis.

  • PR Newswire8 months ago

    Cannabics Pharmaceuticals Files Patent Application on Cannabinoid Modulation of the Microbiome

    Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed the first of a cluster of patent applications with the US Patent & Trademark Office (USPTO) which covers their ongoing work on the use of cannabinoid products for adjusting the varied microbial populations that live on and in the body. The pioneering work based on profiling and modulating patient-derived microbiota, personalizes and profiles individual health status. This will make possible the optimization of pharmacological treatments for patients.

  • Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells
    PR Newswire10 months ago

    Cannabics Pharmaceuticals Files National Phase Applications for Its System and Method for High Throughput Screening of Cancer Cells

    TEL AVIV, Israel, September 25, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced it has filed national phase patent applications for its 'System and Method for High Throughput Screening of Cancer Cells' in the United States, Europe, China, India, Brazil, Canada and Australia. The company has filed the national phase applications after having received a favorable international patentability report from the PCT authorities regarding patent application PCT/IL2016/050471 finding all the claims innovative and inventive. The proprietary technology patented relates to novel means of personalizing cannabis based treatments of cancer utilizing high throughput screening of biopsies and cell lines treated with pure or crude extracts.

  • PR Newswire10 months ago

    Cannabics Pharmaceuticals Files a Patent Application for Sensitivity Tests of Cannabinoids on Patient Derived Tumor Biopsies and CTCs

    Cannabics Pharmaceuticals Inc. (CNBX) announced today that it has filed an extensive provisional patent application with the US Patent & Trademark Office (USPTO) on a new Method for Sensitivity Tests of Cannabinoids on Patient-Derived Tumor Biopsies and CTCs. The method, developed by Cannabics Pharmaceuticals, expands the company's proprietary technology of personalization of cannabinoid medicine.

  • Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells
    PR Newswire11 months ago

    Cannabics Pharmaceuticals Received Positive Report from The Patent Cooperation Treaty Regarding Cannabinoid Personalized Screening of Cancer Cells

    TEL-AVIV, Israel, August 28, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) (CNBX) today announced it received a very positive preliminary international patentability report from the PCT authorities regarding patent application PCT/IL2016/050471 finding all claims innovative and inventive. This PCT report is a major step in the progress of the patent application which is now being launched into several major countries and territories. The company is securing its achievements through a very active and expanding patent portfolio.

  • PR Newswirelast year

    Cannabics Pharmaceuticals Establishes a Human-Cannabis-Cancer Genetics lab to Expand its Personalized Diagnostics

    Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics and cannabinoids. The company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Moran has a PhD in Virology and MSc in clinical pharmacology with vast experience in conceptualizing and executing pharmacological research.